Marex Group’s Basel Medical BMGL Stock Holding History

Marex Group’s Portfolio BMGL Stock Details BMGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,909	Closed	-$105K	–	1189
2025 Q3	$105K	Buy	4,909 +3,749	+323%	+$94K	﹤0.01%	772
2025 Q2	$24.8K	Buy	+1,160	New	+$51K	﹤0.01%	617

Other funds holding BMGL

GSC

Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BIA

Bell Investment Advisors Oakland, California $639M AUM 13.28% 1-Year Est. Return

Marex Group's BMGL Position: Q4 2025 in Review

Marex Group sold out of Basel Medical (BMGL) in Q4 2025, closing a stake of 4,909 shares — an estimated $105K sold.

Marex Group first reported a position in BMGL in Q2 2025 and held it in 2 quarters. The position peaked at $105K in Q3 2025. 9 funds tracked by Wall St. Rank hold BMGL as of Q4 2025.

Marex Group reported no remaining Basel Medical position as of Q4 2025 after selling out during the quarter.
Marex Group sold 4,909 Basel Medical shares in Q4 2025, an estimated $105K.
Marex Group first reported a position in Basel Medical in Q2 2025 and held it in 2 quarters.
Marex Group's Basel Medical position peaked at $105K in Q3 2025.
9 funds tracked by Wall St. Rank held Basel Medical as of Q4 2025.

Based on Marex Group's 13F filing for Q4 2025, filed 12 Feb 2026.